Clinical Trials Browser

Phase 2 × Advanced Refractory Solid Tumors × Immune Checkpoint Inhibitors × Clear all

NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Phase 2 Not yet recruiting

Other solid neoplasm

Advanced Refractory Solid Tumors

NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Phase 2 Unknown

Other solid neoplasm

Advanced Refractory Solid Tumors